phenacetin has been researched along with nifedipine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, EM; Jorgensen, WL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Kallio, J | 1 |
| Lennard, MS; Loft, S; Otton, SV; Poulsen, HE; Tucker, GT | 1 |
| Inoue, K; Mimura, M; Nakamura, S; Oda, H; Ohmori, S; Shimada, T; Yamazaki, H | 1 |
| Li, D; Lin, ZB; Lou, YQ; Wang, X; Zhang, GL; Zhao, X | 1 |
| Mimura, H; Nasu, M; Nemoto, T; Sako, K | 1 |
1 review(s) available for phenacetin and nifedipine
| Article | Year |
|---|---|
[Heritable polymorphisms in oxidative drug metabolism].
Topics: Animals; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; In Vitro Techniques; Mephenytoin; Nifedipine; Oxidation-Reduction; Pharmaceutical Preparations; Phenacetin; Polymorphism, Genetic; Rats | 1990 |
17 other study(ies) available for phenacetin and nifedipine
| Article | Year |
|---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Characterization of metronidazole metabolism by human liver microsomes.
Topics: Acetone; Adult; Benzoflavones; Caffeine; Cytochrome P-450 Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Male; Mephenytoin; Metronidazole; Microsomes, Liver; Middle Aged; Nifedipine; Phenacetin; Quinidine; Theophylline; Tolbutamide | 1991 |
Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans.
Topics: Adrenergic beta-Antagonists; Aniline Compounds; Animals; Antineoplastic Agents; Benzphetamine; Carcinogens; Coumarins; Cytochrome P-450 Enzyme System; Dogs; Erythromycin; Ethanolamines; Ethylmorphine; Guinea Pigs; Humans; Macaca fascicularis; Mephenytoin; Microsomes, Liver; Nifedipine; Oxazines; Oxidation-Reduction; Phenacetin; Phenytoin; Rats; Species Specificity | 1997 |
Effects of Ganoderma lucidum polysaccharide on CYP2E1, CYP1A2 and CYP3A activities in BCG-immune hepatic injury in rats.
Topics: Adjuvants, Immunologic; Animals; BCG Vaccine; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Dealkylation; Ganoderma; Hepatitis; Hydroxylation; Lipid Peroxidation; Liver; Male; Microsomes, Liver; Nifedipine; Nitric Oxide; Oxidation-Reduction; Phenacetin; Polysaccharides; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2007 |
Development of qualitative and quantitative analysis methods in pharmaceutical application with new selective signal excitation methods for 13 C solid-state nuclear magnetic resonance using 1 H T1rho relaxation time.
Topics: Acetaminophen; Antipyrine; beta-Cyclodextrins; Caffeine; Carbon Isotopes; Chemistry, Pharmaceutical; Crystallization; Drug Combinations; Excipients; Indomethacin; Lactose; Magnetic Resonance Spectroscopy; Nifedipine; Pharmaceutical Preparations; Phenacetin; Povidone; Protons; Pyridones; Signal Processing, Computer-Assisted; Technology, Pharmaceutical | 2013 |